Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neovascularization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    171 result(s) found for: Neovascularization. Displaying page 7 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2005-000968-33 Sponsor Protocol Number: 1122334455 Start Date*: 2005-09-05
    Sponsor Name:Medizinische Klinik III, Kardiologie, Universität Frankfurt
    Full Title: Doppel-blinde, randomisierte, kontrollierte Studie zur intraarteriellen Transplantation von Knochenmarks-Progenitorzellen bei Patienten mit chronischer Ischämie bei pAVK (Intraarterial Progenitor...
    Medical condition: Patienten mit angiographisch dokumentierter pAVK Stadium IIb (<50 m Gehstrecke auf dem Laufband, 12% Steigung, 3,2 km/h) mit Auftreten von Claudicatio typischen Beschwerden trotz erfolgter Bewegun...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009909-25 Sponsor Protocol Number: KTvsMM1/09 Start Date*: 2009-05-05
    Sponsor Name:Johann Wolfgang Goethe-Universität Frankfurt
    Full Title: Evaluation of the efficacy and safety of a Macugen monotherapy versus Combined Therapies in the Treatment of Diabetic Retinopathy – a single centre, randomized, prospective Phase II trial
    Medical condition: Medical condition: moderate to severe non-proliferative retinopathy with diabetic cystoid macular edema.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003865-20 Sponsor Protocol Number: 21618 Start Date*: 2021-03-02
    Sponsor Name:Bayer AG
    Full Title: A clinical trial collecting Data from routine ophthalmological examinations of patients who were randomized to either finerenone or placebo in the two Bayer-sponsored Phase 3 clinical trials FIDELI...
    Medical condition: Diabetic Retinopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-024328-53 Sponsor Protocol Number: HULPOFT-2010-01 Start Date*: 2012-05-14
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario La Paz
    Full Title: Phase IIa clinical trial to determine the feasibility and safety of using autologous expanded stem cell (ASC) from fat in the treatment of keratopathy associated with bilateral limbic insufficiency
    Medical condition: Keratopathy associated with bilateral limbic insufficiency.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-004367-57 Sponsor Protocol Number: Start Date*: 2008-05-14
    Sponsor Name:Department of Ophthalmology, Medical University of Graz
    Full Title: Treatment of retinal angiomatous proliferation lesions due to age-related macular degeneration with ranibizumab (Lucentis®) and photodynamic therapy with verteporfin (Visudyne®)
    Medical condition: Subtype of neovascular age-related macular degeneration, so called retinal angiomatous proliferation or RAP.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005290-30 Sponsor Protocol Number: TCA-05-01 Start Date*: 2006-10-18
    Sponsor Name:Department of Ophthalmology, Semmelweis University
    Full Title: A Non- randomized, Single-Center, Open Label Case Series Study of Intravitreal Triamcinolone Acetate Injections (IVTA) Used as Adjunctive to Verteporfin Photodynamic Therapy (PDT) in the Treatment ...
    Medical condition: Age- related macular degeneration with predominantly classic subfoveal choroidal neovascularisation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003923-39 Sponsor Protocol Number: FYB203-03-01 Start Date*: 2020-03-18
    Sponsor Name:Bioeq GmbH
    Full Title: A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients with Neovascular Age Rela...
    Medical condition: Neovascular Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004767-53 Sponsor Protocol Number: CRTH258ADE01 Start Date*: 2020-12-16
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 52-week, two arm, randomized, open-label, multicenter study assessing the efficacy and safety of two different brolucizumab 6 mg dosing regimens for patients with suboptimal anatomically controll...
    Medical condition: neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005091-17 Sponsor Protocol Number: 26285/13 Start Date*: 2014-02-05
    Sponsor Name:POLICLINICO GEMELLI
    Full Title: Variation of choroidal Thickness 15 days after the first ranibizumab intravitreal injection in naïve patients WIth Neovascular age-related macular degeneration: pilot Study. –
    Medical condition: Wet age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004857-24 Sponsor Protocol Number: A4321001 Start Date*: 2005-03-07
    Sponsor Name:Pfizer Global Research and Development
    Full Title: A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety and Efficacy of AG-013958 in Subjects with Subfoveal Choroidal Neovascularization Associate...
    Medical condition: Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    5.1 10025409 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003923-31 Sponsor Protocol Number: OPH2007 Start Date*: 2018-01-30
    Sponsor Name:OPHTHOTECH CORPORATION
    Full Title: A Phase 2A Open-Label Trial to Assess the Safety of Zimura™ (Anti-C5) Administered in Combination With Lucentis® 0.5 mg in Treatment Naïve Subjects with Neovascular Age Related Macular Degeneration
    Medical condition: Neovascular Age Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-002152-32 Sponsor Protocol Number: GR40306 Start Date*: 2019-04-30
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATIO...
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Ongoing) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000106-35 Sponsor Protocol Number: GX29185 Start Date*: 2015-02-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDAR...
    Medical condition: Geographic atrophy
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) AT (Completed) DK (Prematurely Ended) GB (Prematurely Ended) SE (Completed) NL (Prematurely Ended) ES (Completed) BE (Prematurely Ended) PT (Prematurely Ended) SK (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004042-42 Sponsor Protocol Number: GR40844 Start Date*: 2019-05-22
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATIO...
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PT (Completed) DE (Completed) HU (Completed) DK (Completed) ES (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002503-17 Sponsor Protocol Number: 20170542 Start Date*: 2020-08-10
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration
    Medical condition: Neovascular Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) EE (Completed) SK (Completed) ES (Ongoing) CZ (Completed) LT (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003042-15 Sponsor Protocol Number: ACU301 Start Date*: 2007-10-12
    Sponsor Name:Opko Health, Incorporated
    Full Title: A Phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® c...
    Medical condition: Patients with subfoveal choroidal neovascularization associated with Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) ES (Completed) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000107-27 Sponsor Protocol Number: GX29176 Start Date*: 2015-02-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDAR...
    Medical condition: Geographic atrophy
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) AT (Completed) DK (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) SK (Completed) ES (Completed) BE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-004514-32 Sponsor Protocol Number: A5751017 Start Date*: 2006-03-07
    Sponsor Name:
    Full Title: A 102-Week, open label, multicenter trial to investigate the efficacy of macugen for the preservation of visual function in subjects with neovascular age-related macular degeneration (AMD) and to a...
    Medical condition: Age related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025411 Macular degeneration senile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) AT (Prematurely Ended) GB (Completed) ES (Completed) CZ (Prematurely Ended) BE (Completed) DK (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002067-10 Sponsor Protocol Number: BP41321 Start Date*: 2020-07-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-masked, 48-week parallel-group, placebo-controlled, proof-of-concept study to investigate the efficacy and safety of RG7774 in patients with Diabetes Mellitus Type 1 or Type 2 ...
    Medical condition: Diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-000690-73 Sponsor Protocol Number: BAY86-5321/21912 Start Date*: 2023-06-06
    Sponsor Name:Bayer AG
    Full Title: A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive customized Treatment Intervals in Patients ≥50 Years of Age wi...
    Medical condition: Neovascular (wet) age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 09 17:28:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA